Market Size (2016)
2016
$2.64B
Healthcare
Companion Diagnostics Market
By Segment, By Region, And Segment Forecasts, 2016 – 2027
Vertical: HealthcareBase Year: 201912 Sections
Executive Summary
Companion Diagnostics Market — Snapshot
Projected (2027)
2027
$8.08B
CAGR (2016–2027)
10.7%
10.7%Key Players
112+
Companion diagnostic (CDx) is an in vitro diagnostic testing kits majorly used by pharmaceutical companies for the development of personalized medicine. CDx tests provide information about the effective use of a corresponding therapeutic product by analyzing the genetic material. The factors driving the market growth include rising preference of personalized medicine, increasing collaboration among companies and drug-diagnostic co-development and increasing product approval by major players. However, factors such as lack of reimbursement in developing region and limited adaption of CDx and the presence of alternative therapies hamper the market growth.
Key Insight
The Companion Diagnostics Market market is projected to grow at a CAGR of 10.7% from 2016 to 2027.
Market Performance Trend
Historical performance and future projections (2020–2030, USD Billion)
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansMarket Scope & Coverage
What this report covers
- Geographic Coverage: This analysis covers 4 regions: Europe, Asia Pacific, Middle East and Africa, Americas.
- Market Segmentation: The market is analyzed across 5 segments: Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), In Situ Hybridization (ISH), Immunohistochemistry (IHC), Technology_Others. Forecasts are provided for each segment from 2016 to 2027.
- Competitive Landscape: 112 leading companies are profiled, covering market positioning, strategies, and recent developments.
Market Size (USD Mn)
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansMarket Overview
Companion Diagnostics Market — Growth Trajectory
The scope of the global companion diagnostics market study includes market size analysis and a detailed analysis of the manufacturer’s products and strategies. The market has been segmented based on products & services, technology, indication, end user, and region.
Research Objective
To provide a comprehensive analysis of the global companion diagnostics market and its sub-segments, thereby providing a detailed structure of the industryTo provide detailed insights into factors driving and restraining the growth of the global companion diagnostics marketTo estimate the market size of the global companion diagnostics market where 2017 to 2018 would be the historic period, 2019 shall be the base year, and 2020 to 2027 will be the forecast period for the studyTo provide region-wise market value analysis for various segments of the global companion diagnostics marketTo provide strategic profiling of key companies (manufacturers and distributors) present across the globe and comprehensively analyze their competitiveness/competitive landscape in this marketTo provide a distribution chain analysis/value chain for the global companion diagnostics market
Companion Diagnostics Market — Growth Trajectory
Polymerase Chain Reaction (PCR)
Next-Generation Sequencing (NGS)
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansMarket Size Trend (USD Mn)
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansMarket Dimensions
How this market is segmented
- Products & Services Products & Services is broken down into: Assays, Kits, & Reagents, Software & Services.
- Technology Technology is broken down into: Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), In Situ Hybridization (ISH), Immunohistochemistry (IHC), Technology_Others.
- Indication Indication is broken down into: Cancer, Neurological Diseases, Infectious Diseases, Cardiovascular Diseases, Indication_Others.
- End User End User is broken down into: Pharmaceutical & Biopharmaceutical Companies, Contract Research Organizations, Laboratories, End User_Others.
Geographic Analysis
Regional market breakdown
- Europe Europe market size reached $832.01M in 2016 and is projected to reach $2.69B by 2027, growing at a CAGR of 11.3%.
- Asia Pacific Asia Pacific market size reached $644.86M in 2016 and is projected to reach $2.33B by 2027, growing at a CAGR of 12.4%.
- Middle East and Africa Middle East and Africa market size reached $136.05M in 2016 and is projected to reach $393.61M by 2027, growing at a CAGR of 10.1%.
- Americas Americas market size reached $1.03B in 2016 and is projected to reach $2.67B by 2027, growing at a CAGR of 9.1%.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansResearch Methodology
Companion Diagnostics Market — How We Researched This Market
Overview
The research starts with the extensive procurement process of data/information and statistics from company annual reports, government websites, statistic agencies, and paid databases. This information creates a base for the study. This information also helps to define the scope and to narrow down the area for study for the market. This raw information is processed and analyzed to extract crisp data points that currently affect or are likely to affect the industry over the forecast period. After analyzing the information, a proprietary statistical tool is used for market estimation & forecast, which generates the quantitative figures/sizes of the market/sub-segments in the current scenario as well as for over the forecast period.
After estimating the market sizes & estimates, numbers are verified with the industry participants and key opinion leaders. The wide network of industry participants performs a value addition in the research and verify the numbers & estimates of the study. In the last stage of the research process, a final report is prepared, which is then published on different websites as well as distributed through various channels. The below figure contains the different stages of the whole research performed to produce the report.
Data Mining
Data mining is one of the extensive stages of our research process. It involves the procurement of market data and related information through different verified & credible sources. This step helps to obtain the raw information about components in the industry and their deployment, the monetary process for different end-uses, the pool of market participants & the nature of the industry, and the scope of the study. The data mining stage comprises both primary as well as secondary sources of information.
Secondary Research
In the secondary research process, various sources are used to identify and gather industry trends and information for the research process. We at MRFR have access to some of the most diversified and extensive paid databases, which give us the most accurate data/information on market sizes, components, and pricing. Mentioned below is a detailed list of sources that have been used for this study. Please note that this list is not limited to the names as mentioned; we also access other data sources depending on the need.
Primary Research
In the primary research process, in-depth primary interviews are conducted with the CXOs to understand the market share, customer base, pricing strategies, and other necessary information. Besides, in-depth primary interviews are conducted with the CXOs of companies, and others to validate the supply-side information. Moreover, various key industry participants from both the supply and demand side are interviewed to obtain qualitative and quantitative information on the market. In-depth interviews with key primary respondents, including industry professionals, subject matter experts (SMEs), industry consultants, and C-level executives of major companies, are conducted to obtain critical qualitative and quantitative information pertaining to the market, as well as to assess the prospects for market growth during the forecast period. Detailed information on these primary respondents is mentioned below.
Research Methodology for Market Size Estimation
Understanding and penetrating the market in terms of valuation is a crucial task in the process of business research. This again becomes significantly important while investing and choosing business opportunities. In this regard, we at MRFR performs two ways market sizing approach simultaneously, namely top-down and bottom-up approaches. In this step, we place different data points, numeric attributes, information, and industry trends at an appropriate space to deduce the estimates & forecast values over the coming years. We use different mathematical models to estimate the market sizes of different economies and segments. Each of which is further summed up to define the total market.
We at MRFR own a proprietary statistical tool for market estimations, which helps us to comprehend market size estimates & forecasts for different markets and industries.
Bottom-Up Approach
In the bottom-up approach, the revenue of key companies and their shares in the market are assessed to deduce the market size. More than 20 key players operating in the global companion diagnostics market are studied. The segmental revenue of each player is analyzed, and the size for the global companion diagnostics market is extracted from the segmental/product/service revenue with the help of secondary and primary research. The extracted size for the market is then validated with industry experts and partner consultants. This derived market size contributes to around 75% to 85% of the total global market share in terms of revenue for the companion diagnostics market. Using the data triangulation method, the overall global market size is estimated.
Top-Down Approach
The overall market size is then used in the top-down procedure to estimate the size of the other sub-markets with the help of percentage splits of the market segments from secondary and primary research. The demand-side analysis is conducted, in which the expenditure of significant industry players in each region is studied. The end-users considered in the scope of this research study contributes around 70% of the total spent in the companion diagnostics market.
The figure below depicts the process of market estimation using independent tools employed by our analysts to arrive at the sizing of the market.
As a part of the market engineering, both top-down and bottom-up approaches are utilized along with data triangulation models to derive and verify the market sizes and forecast over the coming years.
Data Triangulation
After arriving at the overall market sizes, the total market is divided into several segments and sub-segments. Again, the market breakdown and data triangulation procedures are implemented, wherever applicable, to complete the overall market engineering process and gather the exact statistics for all segments and sub-segments. The data is triangulated by studying various factors and trends from the demand and supply sides. Along with this, the market size is validated using the top-down and bottom-up approaches.
Validation
Validation is the most crucial stage of the report making the process. Validation via an intricately designed feedback process helps us finalize the sizing estimates and forecast for the final collation. Extensive primary research is performed to verify the information. This includes telephonic and personal interviews, e-mails, feedback forms, questionnaires, and polling options/answers with a group of relevant industry participants. Validation helps to duly check the authenticity of the key industry trends, market dynamics, company market share, different business models, and conclusions.
Base Year
2019
Historical Period
2016 – 2019
Forecast Period
2019 – 2027
Primary Interviews
150+
Research Process
Historical data (2016–2019) and forecast period (2019–2027)
1
Problem Definition
- Market scoping
- Objective setting
- Framework design
2
Secondary Research
- Literature review
- Data mining
- Trend analysis
3
Primary Research
- Expert interviews
- Field visits
- Surveys
4
Data Analysis
- Quantitative modeling
- Statistical testing
- Validation
5
Insights & Reporting
- Synthesis
- Recommendations
- Visualization
Research Depth
Our research process spans primary interviews with industry stakeholders combined with comprehensive secondary data analysis, validated through triangulation across multiple independent sources.
Historical vs. Forecast Data
Historical (observed)
Forecast (modelled)
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansCompetitive Landscape & Porter's Five Forces
Companion Diagnostics Market — Competitive Analysis
Threat of New Entrants
The threat of new entrants in the companion diagnostics market is moderate. The companion diagnostics market is growing, hence attracting many new entrants who are looking to make a profit. The entry barriers are high due to strict government norms and regulations which decreases the threat of new entrants. Small and medium-sized companies are creating their space and trying to capture the market share which is mostly untouched by major players. Easy distribution and product differentiations are increasing the threat of new entrants in the global companion diagnostics market.
Bargaining Power of Suppliers
Raw material providers are considered as the suppliers in the global companion diagnostics market. The bargaining power of suppliers is moderate as there is an increase in demand for the raw material by the medical device manufacturing companies. However, the number of suppliers is also high in the market, which is slightly decreasing the bargaining power of suppliers, as switching cost of the market players increases. The increasing prevalence of various diseases and the growing demand for companion diagnostic kit supports the bargaining power of suppliers.
Threat of Substitutes
The threat of substitutes in the global companion diagnostics market is high. The changing healthcare environment and new product development are increasing the threat of substitutes. For the assays, kits, & reagents segment, the threat of substitutes is relatively high as compared to other segments. Consumers tend to use the products which they are using for a long time. Brand loyalty and consumer involvement are decreasing the threat of new substitutes. The major brands are changing and developing the products as per the market need which is another factor that decreases the threat of substitutes. Additionally, there are a lot of substitutes for companion diagnostics, such as molecular diagnostics and in vitro diagnostics. Therefore, the threat of substitutes is high in the global companion diagnostics market.
Bargaining Power of Buyers
The bargaining power of buyers is moderate in the market. The pharmaceutical & biopharmaceutical companies and laboratories are the major buyers in the market.The bargaining power of the buyer can define how easily the buyer can get the products. Buyers in the companion diagnostics market can choose from different companies. Most of the companies are offering the same kind of products so the switching cost of the buyer is relatively low. In this market, buyers are commercial service providers, pharmaceutical companies, research laboratories that are highly skilled and aware of the products that increases the bargaining power of buyers.
Intensity of Rivalry
The intensity of rivalry in the global companion diagnostics market is moderate. Many top and small companies are competing and putting pressure on one another which ultimately decreases the profit. The competition between the companies is affecting the price of the products. Changing technology and market demand are increasing the intensity of the competition in this market. Innovative product development is giving the first movers advantage and most of the companies are following this path. Medium and small manufacturers are focusing more on production and distribution rather than new product development that again creates competition for major brands.
Quantitative Analysis
Regional Breakdown
Regional market breakdown for Companion Diagnostics Market.
Regional Market Size (USD Mn)
Market estimates by geography (2027)
USD Mn
InsightEurope leads with $2.69B by 2027, while Asia Pacific is projected to grow fastest at a 12.4% CAGR.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansRegional Market Data
| REGION | 2016 | 2019 | 2027 | CAGR | SHARE |
|---|---|---|---|---|---|
| Europe | $832.01M | $1.21B | $2.69B | 11.3% | 33% |
| Asia Pacific | $644.86M | $994.06M | $2.33B | 12.4% | 29% |
| Middle East and Africa | $136.05M | $188.67M | $393.61M | 10.1% | 5% |
| Americas | $1.03B | $1.33B | $2.67B | 9.1% | 33% |
| Total | $2.64B | $3.72B | $8.08B | 10.7% | 100% |
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSegment Revenue (2027)
Polymerase Chain Reaction (PCR)
Next-Generation Sequencing (NGS)
In Situ Hybridization (ISH)
Immunohistochemistry (IHC)
Technology_Others
0833166725003333
Segment Market Share
- Polymerase Chain Reaction (PCR)37%
- Next-Generation Sequencing (NGS)32%
- In Situ Hybridization (ISH)16%
- Immunohistochemistry (IHC)7%
- Technology_Others7%
Total Market Size
$8.08B
Market by Segment (2027)
| APPLICATION | REVENUE ($B) | GROWTH RATE | MARKET PENETRATION |
|---|---|---|---|
| Polymerase Chain Reaction (PCR) | $3.03B | 10.7% | 60% |
| Next-Generation Sequencing (NGS) | $2.58B | 10.7% | 67% |
| In Situ Hybridization (ISH) | $1.29B | 10.7% | 87% |
| Immunohistochemistry (IHC) | $598.04M | 10.7% | 78% |
| Technology_Others | $585.91M | 10.7% | 88% |
* Revenue projections based on 2025 estimates. Growth rates represent CAGR 2024–2030. Market penetration indicates current adoption rate within addressable market segments.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansEmpower your Business
with InsightsSave over 20% on
with Insights
Save over 20% on
Annual Subscription
See plans for professionals or small and medium businesses.
Analytics
Companion Diagnostics Market — Key Findings
Analytical insights on Companion Diagnostics Market covering market dynamics, competitive landscape, and strategic outlook.
Key Analytical Findings
The Companion Diagnostics Market market is projected to reach $8.08B by 2027, growing at 10.7% CAGR. The Polymerase Chain Reaction (PCR) segment holds the largest share.
Market Dynamics
A companion diagnostic is an in vitro diagnostic medical kit. Through this test, the healthcare professional can determine whether a particular therapeutic product is effective to the patient or possess any serious side effects or risks.
The key factors driving the market growth are increasing R&D and drug-diagnostic co-development, growing preference for personalized medicine, and increasing technological advancement in the medical device industry. Also, the growing cases of various chronic diseases support the market growth. However, factors such as limited access to targeted therapeutics and CDx and lack of reimbursement in developing regions may hamper the market growth. The increasing use of CDx for different indication areas creates an opportunity to drive the companion diagnostics market.
Market Drivers
Personalized or targeted medicine is one of the upcoming trends in medical innovation. It is one of the most significant fields that creates the need for companion diagnostics products. The healthcare providers are focusing on using CDx to develop new drugs based on specific genetic biomarkers in major fields like oncology, cardiac disease, inflammation, infectious diseases, central nervous system disorders, and many more to improve outcomes for patients. Personalized medicines are also used to treat the diseases caused due to mutation in a specific gene by targeting the specific mutation. To understand both the positive and negative effects of specific drugs or therapy on the patient’s body, the US FDA is working with drug and device manufacturers that are developing certain tests called companion diagnostics.
The growing prevalence of cancer across the globe is increasing the preference for targeted therapy which in turn is affecting the demand for CDx tests. According to Cancer Research UK, there were 17 million new cases of cancer across the world in 2018 in which case lung and breast cancer accounted for the largest share followed by colorectal and prostate cancer.
Additionally, healthcare organizations are involved in launching healthcare programs and platforms to develop better treatment options. For instance, the National Institute of Health has launched a program called “All of Us Research Program” which involves a group of at least one million volunteers from the US to provide inherited data, biological samples, and other health information. Such a large amount of data is used to detect new associations between health, environmental and lifestyle, to identify new potential biomarkers and disease classifications, to create a platform to assist trials of targeted therapies.
The increasing R&D activity and different healthcare programs to support the development of personalized or targeted medicine will increase the demand for companion diagnostic products.
Market Opportunities
The growing research and development activities in the healthcare industry creates an opportunity for new product development using CDx kits. Companion diagnostics is largely used in the development of personalized medicine for cancer patients. The growing R&D activities are diversifying the use of CDx for different therapeutic applications other than cancer. The researchers are working on inflammatory disease (e.g. irritable bowel disease and rheumatoid arthritis), Alzheimer’s disease and infectious diseases using CDx. There are limited companion diagnostic tests for infectious and other chronic diseases.Companies are getting involved in the testing of drugs for the treatment of various disorders creating wide opportunities for the companion diagnostics market to grow. According to the paper published by the National Center for Biotechnology Information (NCBI) in 2018, anti-infectious disease therapies for HIV acts as a new opportunity for CDx market.Additionally, on September 206 the NuSirt Biopharma and OWL Metabolomics entered into a collaboration to develop a blood-based CDx for NuSirt’s NS-0200, currently which is in Phase II trials for non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD).
Thus, the development of efficient medical products for the diagnosis, medication, and prevention of various diseases is greatly needed. The co-development of companion diagnostic devices and their corresponding therapeutic products provides new opportunities for safer and more effective therapies.
Market Restraints
In most countries, delayed reimbursement or lack of funding for diagnostics acts as a key barrier for market growth. Reimbursement for companion diagnostic tests is a complex process. The complexity in the reimbursement process itself acts as a challenge for this market.
In molecular diagnosis, reimbursement is granted for the process or technology and not for the value. In this process, the single test may require multiple processes and sometimes the process repetitions get difficult for the payer to understand what they are paying for. The reimbursement is based on the current procedural terminology (CPT) code. These coding also possess different challenges in reimbursements and leads to delay in payments. The coding acts as a challenge due to the use of different technology for individual tests such as (e.g., immunohistochemistry (IHC), polymerase chain reaction (PCR), fluorescence in situ hybridization (FISH) which increases the complexity. This complex coding structure can lead to insufficient reimbursements for some tests. The high cost of NGS-based CDx decreases the patient preference for the CDx test. Thus, the lack of reimbursement or low funding for diagnosis especially of cancer in the developing countries hamper the market growth.
Strategic Outlook and Future Directions
Near-term growth will likely concentrate in modular bioreactor lines and closed-system media workflows that shorten validation cycles while preserving batch traceability.
Partnerships between CDMOs and instrumentation vendors should accelerate standard datasets for comparability across sites, improving forecasting models used in capacity planning.
Longer horizon, organoid and microphysiological adoption may reshape segment mix; teams that invest early in assay interoperability and cloud QC hooks are better positioned to capture upside without fragmenting their analytics stack.
Market Value by Segment (2027)
Value (USD Mn)
Polymerase Chain Reaction (PCR)
Next-Generation Sequencing (NGS)
In Situ Hybridization (ISH)
Immunohistochemistry (IHC)
Technology_Others
Companies
Key companies profiled in Companion Diagnostics Market
Profiles of 112 companies operating in the Companion Diagnostics Market market, including revenue, employee count, and market positioning where available.
Showing 112 of 112 companies
Guardant H
Guardant Health
Healthcare
Company Headquarters: California, US Founded: 2013 Workforce: 622+ Company Working: Guardant Health (Guardant) is one of the leading precision oncology companies that is focused on helping conquer cancer globally through the use of its proprietary blood-based tests, vast data sets and advanced analytics. The company has provided its offerings to more than 5,000 oncologists, over 40 biopharmaceutical companies, and all 27 of the National Comprehensive Cancer Network centers. The company operates its business through two main geographical segments- the US and International.
Revenue$0.0B
Employees622
Market CapN/A
Founded2012
California, US
Abnova Cor
Abnova Corporation
Healthcare
Abnova Corporation — Healthcare
RevenueN/A
EmployeesN/A
Market CapN/A
FoundedN/A
United States, North America
Icon PLC
Icon PLC
Healthcare
Company Headquarters: Dublin, Ireland Founded: 1990 Workforce: ~38,000 Company Working: Icon plc offers a wide range of clinical development, consulting, and commercialization services across 46 countries. It provides a wide range of services, including clinical research services, commercial positioning, functional services provision, laboratories, medical imaging, real-world intelligence, and site & patient solutions. The organization has extensive experience in diverse therapeutic areas such as cardiovascular, cell, and gene therapies, central nervous system, endocrine and metabolic disorders, infectious diseases, internal medicine and immunology, oncology, and pediatrics. Moreover, it operates in markets and industry verticals such as biosimilar, biotech, government & public health solutions, and pharmaceuticals and has operational facilities across 147 locations.
Revenue$2.4B
Employees38,000
Market CapN/A
Founded1989
Dublin, Ireland
NG Biotech
NG Biotech
Healthcare
Company Headquarters: Guipry, France Founded: 2012 Workforce: 50+ Company Working: NG Biotech (NGB) is into the development, manufacturing, and commercializing of rapid, mobile, and connected diagnostics to modernize diagnosis practice worldwide. The company specializes in research & development, manufacturing, and marketing of a new generation of multiplex, quantitative, and connected rapid diagnostics for biomarker analysis and/or therapy monitoring at the point of care. Its partners include Rennes Atalante Technopole, idea Ille & Vilaine Development, reseauentreprendere Bretagne, and medicine Paris.
RevenueN/A
Employees50
Market CapN/A
Founded2011
Guipry, France
Leica Bios
Leica Biosystems Nussloch GmbH
Healthcare
Company Headquarters: Nussloch, Germany Founded: 1989 Workforce: 1000-5000 Company Working: Leica Biosystems Nussloch GmbH (Leica) operates as a subsidiary of Danaher Corporation and it is a market leader in pathology workflow solutions. The company concentrates on providing quality products and improving diagnostics. It operates in histology, pathology, histopathology, digital pathology, neuropathology, cancer diagnostics, laboratory workflow solutions, histology sample preparation, in situ hybridization (ISH) advanced staining, routine special staining, consumables, and microtomy.
Revenue$15.5B
Employees5,000
Market CapN/A
Founded1988
Nussloch, Germany
Illumina I
Illumina Inc.
Healthcare
Company Headquarters: California, US Founded: 1998 Workforce: 7,700+ Company Working: Illumina, Inc. (Illumina) operates in genomics, an industry at the intersection of biology and technology. Illumina focuses on innovating and improving human health by offering a wide range of innovative products. Its initial products have enabled researchers to explore DNA at an entirely new scale and helped them create the first map of gene variations associated with health, disease, and drug response. It serves customers in the research, clinical, and applied markets. Its products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. It has a presence in major regions such as North America, Europe, and Asia.
Revenue$2.4B
Employees7,700
Market CapN/A
Founded1997
California, US
Page 1 of 19
…
Go to page
Powering the world's best teams.
From next-gen startups to established enterprises.
What our clients say
Trusted by forward-thinking businesses
for data-driven intelligence
Noah Malgeri
Co-Founder, Mojave Rail Fabrication Limited
This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job.
Michael Robert
Manager, JavolVision
Thanks, I am so happy that we worked together. Maybe we still can work together in the future.
Joseph Aguayo
Sales Operations & Pricing Manager, Intel
Thanks. It's been a pleasure working with you, please use me as reference with any other Intel employees.
Bong Lau
Sales Leader, Bamberg
We bought your "2025 report" in 2020. Everything is fine and very good.
Peter Groot Koerkamp
Account and Business Manager, EFS-Holland BV
Thanks for sending the report it gives us a good global view of the Betaïne market.
Younghwan Choi
Senior Retail Manager, LG Chem
We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.
Mark Irwin
Management Consultant, Level 21
I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.
Rob Kooiker
Group Product Manager HVAC & Fire Protection GMA, Rockwool
I have been reading the first document or the study, the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!
Jason Lee
R&D Director, Seojin
Thanks for your great support. Appreciate it. Well received report. It helps us to understand market well. We're planning other area of survey in the future, let's keep in touch.
Akif Moroglu
Strategy & Business Development Director, Dogan Holding
We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.
Noah Malgeri
Co-Founder, Mojave Rail Fabrication Limited
This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job.
Michael Robert
Manager, JavolVision
Thanks, I am so happy that we worked together. Maybe we still can work together in the future.
Joseph Aguayo
Sales Operations & Pricing Manager, Intel
Thanks. It's been a pleasure working with you, please use me as reference with any other Intel employees.
Bong Lau
Sales Leader, Bamberg
We bought your "2025 report" in 2020. Everything is fine and very good.
Peter Groot Koerkamp
Account and Business Manager, EFS-Holland BV
Thanks for sending the report it gives us a good global view of the Betaïne market.
Younghwan Choi
Senior Retail Manager, LG Chem
We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.
Mark Irwin
Management Consultant, Level 21
I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.
Rob Kooiker
Group Product Manager HVAC & Fire Protection GMA, Rockwool
I have been reading the first document or the study, the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!
Jason Lee
R&D Director, Seojin
Thanks for your great support. Appreciate it. Well received report. It helps us to understand market well. We're planning other area of survey in the future, let's keep in touch.
Akif Moroglu
Strategy & Business Development Director, Dogan Holding
We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.
Companion Diagnostics Market
Starting from
$4,950